BlackRock’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-2,781,344
| Closed | -$94M | – | 5785 |
|
|
2021
Q2 | $94M | Buy |
2,781,344
+131,642
| +5% | +$3.35M | ﹤0.01% | 2298 |
|
|
2021
Q1 | $62M | Buy |
2,649,702
+53,103
| +2% | +$1.61M | ﹤0.01% | 2485 |
|
|
2020
Q4 | $74.8M | Buy |
2,596,599
+524,934
| +25% | +$13.2M | ﹤0.01% | 2242 |
|
|
2020
Q3 | $42M | Buy |
2,071,665
+230,734
| +13% | +$5.63M | ﹤0.01% | 2401 |
|
|
2020
Q2 | $55.3M | Buy |
1,840,931
+527,230
| +40% | +$19M | ﹤0.01% | 2191 |
|
|
2020
Q1 | $41.3M | Buy |
1,313,701
+226,117
| +21% | +$7.86M | ﹤0.01% | 2177 |
|
|
2019
Q4 | $51.2M | Buy |
1,087,584
+240,129
| +28% | +$6.93M | ﹤0.01% | 2345 |
|
|
2019
Q3 | $5.47M | Buy |
847,455
+27,023
| +3% | +$226K | ﹤0.01% | 3461 |
|
|
2019
Q2 | $10.1M | Buy |
820,432
+94,107
| +13% | +$1.05M | ﹤0.01% | 3253 |
|
|
2019
Q1 | $9.84M | Buy |
726,325
+619,868
| +582% | +$5.56M | ﹤0.01% | 3117 |
|
|
2018
Q4 | $427K | Sell |
106,457
-83,179
| -44% | -$502K | ﹤0.01% | 4094 |
|
|
2018
Q3 | $1.28M | Buy |
+189,636
| New | +$1.81M | ﹤0.01% | 3893 |
|
BlackRock's CNST Position: Q3 2021 in Review
BlackRock sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q3 2021, closing a stake of 2,781,344 shares — an estimated $94M sold.
BlackRock first reported a position in CNST in Q3 2018 and held it in 12 quarters. The position peaked at $94M in Q2 2021. 0 funds tracked by Wall St. Rank hold CNST as of Q3 2021.
- BlackRock reported no remaining Constellation Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
- BlackRock sold 2,781,344 Constellation Pharmaceuticals, Inc. shares in Q3 2021, an estimated $94M.
- BlackRock first reported a position in Constellation Pharmaceuticals, Inc. in Q3 2018 and held it in 12 quarters.
- BlackRock's Constellation Pharmaceuticals, Inc. position peaked at $94M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q3 2021.
Based on BlackRock's 13F filing for Q3 2021, filed 9 Nov 2021.